Axena Health has partnered with UpScriptHealth, a direct-to-consumer telehealth company, to provide consultation and treatment for women experiencing urinary incontinence. Axena's Leva Pelvic Health System, an FDA-cleared intravaginal device, aids in pelvic floor muscle training (PFMT) and can be used at home. The system is designed for mixed, mild-to-moderate-urgency urinary incontinence and chronic fecal incontinence, requiring just five minutes of daily use over eight to twelve weeks. Women seeking the treatment complete a medical history questionnaire and have an online consultation with an UpScriptHealth provider for a prescription.
The partnership leverages telehealth to address the shortage of OB-GYNs and improve access to care, particularly for those in remote areas. Jim O’Connor, interim CEO of Axena Health, highlighted the importance of involving healthcare providers in the treatment process while ensuring that obtaining a prescription does not hinder access to care. The Leva Pelvic Health System allows women to track their bladder leakage symptoms, enabling continuous involvement of their regular healthcare providers.
Axena Health acquired the Leva Pelvic Health System from Renovia and raised $25 million in Series A funding last year to expand access to this pelvic floor digital therapeutic. UpScriptHealth, Axena's pharmacy distributor since March 2023, has also collaborated with Eversana to launch a direct-to-patient platform to accelerate global access to therapies. Other companies in the female pelvic health space include SWORD Health, which launched Bloom, a physical therapy product focused on pelvic health and pain, in 2022.
A 2022 study published in Urogynecology revealed that 28 million women in the U.S. suffer from moderate to severe urinary incontinence, underscoring the significant need for innovative solutions like the Leva Pelvic Health System. This partnership aims to enhance care accessibility and improve outcomes for women dealing with urinary incontinence.
Click here to read the original news story.